Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib

Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for patients with CD19(+) B-cell malignancies. Combination strategies that improve CAR T-cell potency, limit tumor environment–mediated immune dysfunction, and directly reduce tumor burden may increase the potential for durable...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Immunother
Glavni autori: Qin, Jim S., Johnstone, Timothy G., Baturevych, Alex, Hause, Ronald J., Ragan, Seamus P., Clouser, Christopher R., Jones, Jon C., Ponce, Rafael, Krejsa, Cecile M., Salmon, Ruth A., Ports, Michael O.
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2020
Teme:
Basic Studies
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7144752/
https://ncbi.nlm.nih.gov/pubmed/31899702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000307
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items